| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| BUY | SELL | SELL | SELL | SELL |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 1.23▲ | 1.22▲ | 1.23▲ | 1.29▼ | 1.46▼ |
| MA10 | 1.22▲ | 1.23▲ | 1.27▼ | 1.38▼ | 1.77▼ |
| MA20 | 1.21▲ | 1.28▼ | 1.30▼ | 1.52▼ | 3.06▼ |
| MA50 | 1.23▲ | 1.31▼ | 1.36▼ | 1.88▼ | 5.28▼ |
| MA100 | 1.27▼ | 1.37▼ | 1.44▼ | 3.39▼ | 13.36▼ |
| MA200 | 1.30▼ | 1.46▼ | 1.66▼ | 5.04▼ | 25.16▼ |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | 0.004▲ | -0.005▼ | -0.007▼ | 0.004▲ | -0.056▼ |
| RSI | 62.117▲ | 40.544▼ | 39.116▼ | 32.738▼ | 32.937▼ |
| STOCH | 83.333▲ | 15.842▼ | 7.071▼ | 16.979▼ | 6.666▼ |
| WILL %R | 0.000▲ | -72.727 | -74.286 | -92.135▼ | -98.752▼ |
| CCI | 161.616▲ | -51.515 | -91.721 | -113.440▼ | -117.220▼ |
|
Monday, December 22, 2025 12:13 PM
US biotech Altimmune (Nasdaq: ALT) said its experimental MASH drug pemvidutide delivered sustained improvements in key non-invasive fibrosis markers through 48 weeks in a mid-stage trial, extending ...
|
|
Friday, December 19, 2025 08:58 AM
Altimmune reports positive 48-week Phase 2b data for pemvidutide in MASH, showing fibrosis improvement, weight loss, and strong tolerability.
|
|
Tuesday, December 02, 2025 08:01 AM
LAS VEGAS--(BUSINESS WIRE)--ALT 5 Sigma Corporation (the “Company” or “ALT5”) (NASDAQ: ALTS)(FRA: 5AR1) today announced that it received a notification letter (the “Letter”) from the Nasdaq Stock ...
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 22/12/25 | 1.33 | 1.36 | 1.195 | 1.23 | 5,426,369 |
| 19/12/25 | 1.35 | 1.38 | 1.29 | 1.31 | 4,594,000 |
| 18/12/25 | 1.29 | 1.42 | 1.27 | 1.33 | 5,877,111 |
| 17/12/25 | 1.33 | 1.35 | 1.22 | 1.24 | 3,485,132 |
| 16/12/25 | 1.33 | 1.40 | 1.23 | 1.33 | 3,384,000 |
| 15/12/25 | 1.46 | 1.47 | 1.31 | 1.355 | 3,149,184 |
| 12/12/25 | 1.52 | 1.62 | 1.47 | 1.48 | 2,317,076 |
| 11/12/25 | 1.48 | 1.55 | 1.43 | 1.52 | 1,780,500 |
| 10/12/25 | 1.47 | 1.55 | 1.3501 | 1.51 | 3,848,240 |
| 09/12/25 | 1.38 | 1.60 | 1.37 | 1.50 | 4,944,200 |
|
|
||||
|
|
||||
|
|